Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 10, 2015, Pages 1739-1745

  Akil, Ayman ^a   Zhang, Qing ^b   Mumaw, Christen L ^a,c   Raiker, Nisha ^a,c   Yu, Jeffrey ^a,c   Velez de Mendizabal, Nieves ^a   Haneline, Laura S ^a,c   Robertson, Kent A ^a   Skiles, Jodi ^a   Diaz Ricart, Maribel ^d   Carreras, Enric ^d,e   Renbarger, Jamie ^a,c   Hanash, Samir ^f   Bies, Robert R ^a   Paczesny, Sophie ^a,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOSPITAL CLÍNIC   (Spain)

^e University of Texas MD Anderson Cancer Center ^*  (Spain)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers; Proteomics; Sinusoidal obstruction syndrome; SOS; Veno occlusive disease; VOD

Indexed keywords

ANGIOPOIETIN 2; CD97 ANTIGEN; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; L FICOLIN PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN; SUPPRESSION OF TUMORIGENICITY 2 PROTEIN; THROMBOMODULIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; FICOLIN; LECTIN; TIMP1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOASSAY; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; TREATMENT RESPONSE; ADVERSE EFFECTS; BAYES THEOREM; BLOOD; COHORT ANALYSIS; HEPATIC VENO-OCCLUSIVE DISEASE; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; PROCEDURES; RISK ASSESSMENT; YOUNG ADULT;

ADOLESCENT; ADULT; BAYES THEOREM; BIOMARKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE-1; LECTINS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROGNOSIS; PROTEOMICS; RISK ASSESSMENT; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASCULAR CELL ADHESION MOLECULE-1; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84941274069     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.07.004     Document Type: Article

References (29)

1. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363:2091-2101.
2. Coppell J.A., Richardson P.G., Soiffer R., et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010, 16:157-168.
3. Carreras E., Diaz-Beya M., Rosinol L., et al. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant 2011, 17:1713-1720.
4. Chao N. How I treat sinusoidal obstruction syndrome. Blood 2014, 123:4023-4026.
5. Mohty M., Malard F., Abecassis M., et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2015, 50:781-789.
6. McDonald G.B., Sharma P., Matthews D.E., et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984, 4:116-122.
7. Dix S.P., Wingard J.R., Mullins R.E. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996, 17:225-230.
8. van den Broek M.A., Vreuls C.P., Winstanley A., et al. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 2013, 20:1462-1469.
9. Wadleigh M., Richardson P.G., Zahrieh D., et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003, 102:1578-1582.
10. Cutler C., Stevenson K., Kim H.T., et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008, 112:4425-4431.
11. Kebriaei P., Wilhelm K., Ravandi F., et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk 2013, 13:296-301.
12. Carmona A., Diaz-Ricart M., Palomo M., et al. Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. Biol Blood Marrow Transplant 2013, 19:1439-1445.
13. Jones R.J., Lee K.S., Beschorner W.E., et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987, 44:778-783.
14. Richardson P.G., Murakami C., Jin Z., et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002, 100:4337-4343.
15. Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol 2015, 168:481-491.
16. Faca V., Coram M., Phanstiel D., et al. Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J Proteome Res 2006, 5:2009-2018.
17. Faca V., Pitteri S.J., Newcomb L., et al. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res 2007, 6:3558-3565.
18. Paczesny S., Braun T.M., Levine J.E., et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010, 2:13ra2.
19. Paczesny S., Krijanovski O.I., Braun T.M., et al. A biomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
20. Fiema B., Harris A.C., Gomez A., et al. High throughput sequential ELISA for validation of biomarkers of acute graft-versus-host disease. J Vis Exp 2012, 10.3791/4247.
21. Ferrara J.L., Harris A.C., Greenson J.K., et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011, 118:6702-6708.
22. Vander Lugt M.T., Braun T.M., Hanash S., et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013, 369:529-539.
23. Witten I., Frank E., Hall M. Data mining: practical machine learning tools and techniques 2011, Morgan Kaufmann, Burlington, MA. 3rd ed.
24. Salat C., Holler E., Kolb H.J., et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997, 89:2184-2188.
25. Cutler C., Kim H.T., Ayanian S., et al. Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant 2010, 16:1180-1185.
26. Luft T., Dietrich S., Falk C., et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011, 118:1685-1692.
27. Palomo M., Diaz-Ricart M., Carbo C., et al. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 2010, 16:985-993.
28. Brinkmann C.R., Jensen L., Dagnaes-Hansen F., et al. Mitochondria and the lectin pathway of complement. J Biol Chem 2013, 288:8016-8027.
29. Paczesny S., Hakim F.T., Pidala J., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant 2015, 21:780-792.